PT3648788T - Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante - Google Patents

Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante

Info

Publication number
PT3648788T
PT3648788T PT187464581T PT18746458T PT3648788T PT 3648788 T PT3648788 T PT 3648788T PT 187464581 T PT187464581 T PT 187464581T PT 18746458 T PT18746458 T PT 18746458T PT 3648788 T PT3648788 T PT 3648788T
Authority
PT
Portugal
Prior art keywords
patients
administration
treatment
von willebrand
gastrointestinal bleeding
Prior art date
Application number
PT187464581T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PT3648788T publication Critical patent/PT3648788T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT187464581T 2017-07-07 2018-07-09 Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante PT3648788T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762530027P 2017-07-07 2017-07-07

Publications (1)

Publication Number Publication Date
PT3648788T true PT3648788T (pt) 2024-08-23

Family

ID=63036433

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187464581T PT3648788T (pt) 2017-07-07 2018-07-09 Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante

Country Status (15)

Country Link
US (5) US10632176B2 (enExample)
EP (2) EP3648788B1 (enExample)
JP (2) JP7307047B2 (enExample)
KR (1) KR20200037235A (enExample)
CN (1) CN111436193A (enExample)
AU (2) AU2018298233B2 (enExample)
BR (1) BR112020000321A2 (enExample)
CA (1) CA3069295A1 (enExample)
CO (1) CO2020001322A2 (enExample)
DK (1) DK3648788T3 (enExample)
ES (1) ES2986574T3 (enExample)
FI (1) FI3648788T5 (enExample)
PL (1) PL3648788T3 (enExample)
PT (1) PT3648788T (enExample)
WO (1) WO2019010497A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020000321A2 (pt) 2017-07-07 2020-07-14 Baxalta Incorporated método para tratamento de sangramento gastrointestinal em um sujeito com doença de von willebrand.
US20220395560A1 (en) * 2019-02-01 2022-12-15 Takeda Pharmaceutical Company Limited METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
US12128090B2 (en) * 2019-02-01 2024-10-29 Takeda Pharmaceutical Company Limited Methods of prophylactic treatment using recombinant VWF (rVWF)
WO2021032646A1 (en) * 2019-08-16 2021-02-25 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
AU591671B2 (en) 1985-04-11 1989-12-14 Children's Medical Center Corporation Von willebrand factor
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
PL1835938T3 (pl) 2004-12-27 2014-01-31 Baxalta Inc Koniugaty polimer-czynnik von Willebrandta
WO2007077217A2 (en) 2006-01-04 2007-07-12 Baxter International Inc. Oligopeptide-free cell culture media
US9107902B2 (en) 2007-06-13 2015-08-18 Csl Behring Gmbh Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
JP2011503101A (ja) 2007-11-09 2011-01-27 バクスター・インターナショナル・インコーポレイテッド 修飾された組換え第viii因子およびフォンウィルブランド因子ならびにその使用方法
JP5784907B2 (ja) 2007-12-28 2015-09-24 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 組換え型vwf製剤
RU2528855C2 (ru) 2008-06-24 2014-09-20 Цсл Беринг Гмбх Модифицированный фактор виллебранда с удлиненным полупериодом существования in vivo, его применения и способы получения
AR074054A1 (es) 2008-10-21 2010-12-22 Baxter Healthcare Sa Formulaciones farmaceuticas de factor de von willebrand recombinante liofilizado
AU2010279463A1 (en) 2009-08-04 2012-03-01 Baxter Healthcare S.A. Transgenic mouse knockout for FVIII and VWF - model of hemophilia A
EP2591094B1 (en) 2010-07-08 2018-09-05 Baxalta GmbH Method of producing recombinant adamts13 in cell culture
EP3412305B1 (en) * 2011-06-10 2021-01-06 Baxalta GmbH Treatment of coagulation disease by administration of recombinant vwf
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
BR112020000321A2 (pt) 2017-07-07 2020-07-14 Baxalta Incorporated método para tratamento de sangramento gastrointestinal em um sujeito com doença de von willebrand.

Also Published As

Publication number Publication date
US20230122958A1 (en) 2023-04-20
AU2018298233B2 (en) 2025-04-24
US11529395B2 (en) 2022-12-20
BR112020000321A2 (pt) 2020-07-14
US20200206318A1 (en) 2020-07-02
US20210169989A1 (en) 2021-06-10
RU2020105682A3 (enExample) 2021-10-15
ES2986574T3 (es) 2024-11-12
AU2018298233A1 (en) 2020-01-30
JP2023123738A (ja) 2023-09-05
EP4424366A3 (en) 2024-12-04
JP2020526525A (ja) 2020-08-31
FI3648788T3 (fi) 2024-08-16
EP4424366A2 (en) 2024-09-04
FI3648788T5 (fi) 2024-09-09
JP7641327B2 (ja) 2025-03-06
PL3648788T3 (pl) 2024-10-07
JP7307047B2 (ja) 2023-07-11
EP3648788B1 (en) 2024-05-22
KR20200037235A (ko) 2020-04-08
AU2025205392A1 (en) 2025-09-25
RU2020105682A (ru) 2021-08-10
US10905746B2 (en) 2021-02-02
EP3648788A1 (en) 2020-05-13
US12016904B2 (en) 2024-06-25
US10632176B2 (en) 2020-04-28
CN111436193A (zh) 2020-07-21
CO2020001322A2 (es) 2020-02-18
US20240316160A1 (en) 2024-09-26
DK3648788T3 (da) 2024-08-19
CA3069295A1 (en) 2019-01-10
US20190091299A1 (en) 2019-03-28
WO2019010497A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
MX2015015249A (es) Peptidos terapeuticos.
PT3648788T (pt) Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
CL2015002456A1 (es) Tratamiento de la deficiencia de la hormona del crecimiento pediátrica con análogos de la hormona del crecimiento humano
EP3071280A4 (en) TREATMENT CATHETER WITH THERAPEUTIC ENERGY SUPPLY
EP3318879A4 (en) Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
MA50358A (fr) Sémaglutide en thérapie médicale
EP3643784A4 (en) RECOMBINANT HUMAN BASIC FIBROBLASTIC GROWTH FACTOR (RH-BFGF) AND PHARMACEUTICAL COMPOSITION INCLUDING RH-BFGF
SG11201610947UA (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
SG10201912768YA (en) Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
EA201890163A1 (ru) Композиция фолликулостимулирующего гормона млекопитающего с повышенной стабильностью
CO7131377A2 (es) Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos
PT3648787T (pt) Tratamento de doentes com doença de von willebrand grave submetidos a cirurgia eletiva por administração de vwf recombinante
EA201991531A1 (ru) Способы лечения композициями линаклотида с отсроченным высвобождением
AR104194A1 (es) Composición del factor de von willebrand
EP3331559A4 (en) IMMUNE-LEADING RECOMBINANT DENGUE PROTEIN
CY1124859T1 (el) Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων
EP3823591A4 (en) MICRONIZED HUMAN INJECTABLE INSULIN
IT201700009222A1 (it) Composizione per la preparazione del paziente per la colonscopia virtuale
HK40013462A (en) Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
PH12016500509B1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
RU2014104258A (ru) Медицинский рассасывающийся шовный материал терапевтического действия